Plasma chromogranin a levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5661-5669

  Chou, Wen Chi ^a,b   Chen, Jen Shi ^a   Hung, Y U Shin ^a   Hsu, Jun T E ^a   Chen, Tse Ching ^a   Sun, Chien Feng ^a   Lu, Chang Hsien ^a   Hwang, Tsann Long ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Biomarker; Chromogranin A; Gastroenteropancreatic.; Neuroendocrine tumor; Tumor response

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHROMOGRANIN A; CYTOTOXIC AGENT; EVEROLIMUS; PROTON PUMP INHIBITOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SUNITINIB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; CARCINOID; CHEMOTHERAPY; CHROMOGRANIN A BLOOD LEVEL; COLON TUMOR; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCAGONOMA; HUMAN; HYPERTENSION; INSULINOMA; KIDNEY FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS TUMOR; PERITONEUM METASTASIS; PREDICTION; PRIMARY TUMOR; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE TUMOR; STOMACH TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR LOCALIZATION; VIPOMA; AREA UNDER THE CURVE; BLOOD; CANCER GRADING; CANCER STAGING; FOLLOW UP; INTESTINAL NEOPLASMS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CHROMOGRANIN A; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; ROC CURVE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84917707214     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R and Gullo L: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 13: 55-58, 2001.
2. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R and Tomassetti P: Chromogranin A: Is it a useful marker of neuroendocrine tumors? J Clin Oncol 25: 1967-1973, 2007.
3. Nobels F, Kwekkeboom D, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R and Lamberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha subunit of glycoprotein hormones. J Clin Endocrinol Metab 82: 2622-2628, 1997.
4. Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R and De Apollonia L: Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 14: 1135-1141, 2003.
5. Namwongprom S, Wong FC, Tateishi U, Kim EE and Boonyaprapa S: Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 22: 237-423, 2008.
6. Nehar D, Lombard-Bohas C, Olivieri S, Claustrat B, Chayvialle JA, Penes MC, Sassolas G and Borson-Chazot F: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol 60: 644-652, 2004.
7. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, De Braud F, Delle Fave G, Dogliotti L, degli Uberti EC and Italian CromaNet Working Group: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr Relat Cancer 14: 473-482, 2007.
8. Kim T, Tao-Cheng JH, Eiden LE and Loh YP: Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 106: 499-509, 2001.
9. Taupenot L, Harper KL and O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 348: 1134-1149, 2003.
10. Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié P and Schlumberger M: Neuro-specific enolase and chromogranin A as markers of neuroendocrine tumours. British J Cancer 78: 1102-1107, 1998.
11. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E and Bombardieri E: Chromogranin A, neuron-specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858-865, 1999.
12. Walter T, Chardon L, Chopin-laly X, Raverot V, Caffin AG, Chayvialle JA, Scoazec JY and Lombard-Bohas C: Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur J Cancer 48: 1766-1773, 2012.
13. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E and Oberg K: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: 685-90, 1997.
14. Ekeblad S, Skogseid B, Dunder K, Oberg K and Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14: 7798-7803, 2008.
15. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A and Öberg KE: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96: 3741-3749, 2011.
16. Korse CM, Bonfrer JM, Aaronson NK, Hart AA and Taal BG: Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 89: 296-301, 2009.
17. Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME and Meyer T: Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol 31: 365-372, 2013.
18. Massironi S, Conte D, Sciola V, Spampatti MP, Ciafardini C, Valenti L, Rossi RE and Peracchi M: Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 105: 2072-2078, 2010.
19. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF, Plöckinger U; Mallorca Consensus Conference participants and European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 90: 194-202, 2009.
20. Chou WC, Hung YS, Hsu JT, Chen JS, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC and Sun CF: Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 95: 344-350, 2012.
21. Bosman FT; World Health Organization; International Agency for Research on Cancer. Fourth edition: World Health Organization Classification of Tumours of the Digestive System. IARC Press: Lyon, 2010.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
23. NCCN Clinical Practice Guidelines in Oncology/Neuroendocrine Tumors. Version 1.2014. http://www.nccn.org/professionas/physician-gls/ neuroendocrine.pdf. Last accessed 19 Nov 2013.
24. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV and Kidd M: Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 17: 2427-2443, 2010.
25. Vezzosi D, Walter T, Laplanche A, Raoul JL, Dromain C, Ruszniewski P, d'Herbomez M, Guigay J, Mitry E, Cadiot G, Leboulleux S, Lombard-Bohas C, Borson-Chazot F, Ducreux M and Baudin E: Chromogranin A measurement in metastatic welldifferentiated gastroenteropancreatic neuroendocrine carcinoma: screening for false positives and a prospective follow-up study. Int J Biol Markers 26: 94-101, 2011.
26. Funa K, Eriksson B, Wilander E and Oberg K: In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors. Histochemistry 95: 555-559, 1991.
27. Fahrenkamp AG, Wibbeke C, Winde G, Ofner D, Böcker W, Fischer-Colbrie R and Schmid KW: Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract. Virchows Arch 426: 361-367, 1995.
28. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K and RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.
29. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard- Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R and Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513, 2011.